Papandreou, ChristopherBullò, MònicaTinahones, Francisco JoséMartínez-González, Miguel ÁngelCorella, DoloresFragkiadakis, Georgios ALópez-Miranda, JoséEstruch, RamonFitó, MontserratSalas-Salvadó, Jordi2025-01-072025-01-072017-09-021743-7075https://hdl.handle.net/10668/25790Limited prospective studies have examined changes in non-alcoholic fatty-liver disease (NAFLD) related serum-metabolites and none the effects of NAFLD-reversion. We aimed to evaluate whether perturbations in metabolites indicate predisposition to NAFLD development and to assess the effects of NAFLD reversion on metabolite profiles. A targeted liquid-chromatography tandem mass-spectrometry metabolic profiling (n = 453 metabolites) approach was applied, using serum from 45 subjects of the PREDIMED study, at baseline and after a median 3.8-year follow-up. NAFLD was determined using the hepatic steatosis index; with three groups classified and studied: Group 1, not characterized as NAFLD cases during the follow-up (n = 15); Group 2, characterized as NAFLD during the follow-up (n = 15); Group 3, characterized as NAFLD-reversion during the follow-up (n = 15). At baseline, significantly lower storage and transport lipids (triacylglycerols and cholesteryl esters), several monoetherglycerophosphocholines, acylglycerophosphocholines, ceramides and ceramide to sphingomyelin ratio (P  The rearrangement of lipid biosynthesis and serum transport may indicate predisposition to NAFLD development. Despite an expected reduction of hepatic lipotoxicity and improved hepatic function in the participants of the study characterized as NAFLD-reversing, the side effects of NAFLD in serum metabolic profiles remained present. The trial is registered at ISRCTN35739639. Registration date: 5th October 2005.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Fatty acid metabolismHepatic lipotoxicityMetabolomicsNon-alcoholic fatty liver diseaseresearch article28878811open access10.1186/s12986-017-0213-3PMC5581927https://nutritionandmetabolism.biomedcentral.com/track/pdf/10.1186/s12986-017-0213-3https://pmc.ncbi.nlm.nih.gov/articles/PMC5581927/pdf